Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 143

1.

The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice.

Thomas EA, Coppola G, Desplats PA, Tang B, Soragni E, Burnett R, Gao F, Fitzgerald KM, Borok JF, Herman D, Geschwind DH, Gottesfeld JM.

Proc Natl Acad Sci U S A. 2008 Oct 7;105(40):15564-9. doi: 10.1073/pnas.0804249105. Epub 2008 Sep 30.

2.

Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease.

Jia H, Pallos J, Jacques V, Lau A, Tang B, Cooper A, Syed A, Purcell J, Chen Y, Sharma S, Sangrey GR, Darnell SB, Plasterer H, Sadri-Vakili G, Gottesfeld JM, Thompson LM, Rusche JR, Marsh JL, Thomas EA.

Neurobiol Dis. 2012 May;46(2):351-61.

3.

Oral administration of the pimelic diphenylamide HDAC inhibitor HDACi 4b is unsuitable for chronic inhibition of HDAC activity in the CNS in vivo.

Beconi M, Aziz O, Matthews K, Moumné L, O'Connell C, Yates D, Clifton S, Pett H, Vann J, Crowley L, Haughan AF, Smith DL, Woodman B, Bates GP, Brookfield F, Bürli RW, McAllister G, Dominguez C, Munoz-Sanjuan I, Beaumont V.

PLoS One. 2012;7(9):e44498. doi: 10.1371/journal.pone.0044498. Epub 2012 Sep 4.

4.

HDAC inhibition imparts beneficial transgenerational effects in Huntington's disease mice via altered DNA and histone methylation.

Jia H, Morris CD, Williams RM, Loring JF, Thomas EA.

Proc Natl Acad Sci U S A. 2015 Jan 6;112(1):E56-64. doi: 10.1073/pnas.1415195112. Epub 2014 Dec 22.

5.

Selective histone deacetylase (HDAC) inhibition imparts beneficial effects in Huntington's disease mice: implications for the ubiquitin-proteasomal and autophagy systems.

Jia H, Kast RJ, Steffan JS, Thomas EA.

Hum Mol Genet. 2012 Dec 15;21(24):5280-93. doi: 10.1093/hmg/dds379. Epub 2012 Sep 10.

6.
7.

Effects of the Pimelic Diphenylamide Histone Deacetylase Inhibitor HDACi 4b on the R6/2 and N171-82Q Mouse Models of Huntington's Disease.

Chen JY, Wang E, Galvan L, Huynh M, Joshi P, Cepeda C, Levine MS.

PLoS Curr. 2013 Feb 5;5. pii: ecurrents.hd.ec3547da1c2a520ba959ee7bf8bdd202. doi: 10.1371/currents.hd.ec3547da1c2a520ba959ee7bf8bdd202.

8.

Genetic knock-down of HDAC7 does not ameliorate disease pathogenesis in the R6/2 mouse model of Huntington's disease.

Benn CL, Butler R, Mariner L, Nixon J, Moffitt H, Mielcarek M, Woodman B, Bates GP.

PLoS One. 2009 Jun 1;4(6):e5747. doi: 10.1371/journal.pone.0005747.

9.

Mitochondrial-dependent Ca2+ handling in Huntington's disease striatal cells: effect of histone deacetylase inhibitors.

Oliveira JM, Chen S, Almeida S, Riley R, Gonçalves J, Oliveira CR, Hayden MR, Nicholls DG, Ellerby LM, Rego AC.

J Neurosci. 2006 Oct 25;26(43):11174-86.

10.

Genetic knock-down of HDAC3 does not modify disease-related phenotypes in a mouse model of Huntington's disease.

Moumné L, Campbell K, Howland D, Ouyang Y, Bates GP.

PLoS One. 2012;7(2):e31080. doi: 10.1371/journal.pone.0031080. Epub 2012 Feb 8.

11.

Histones associated with downregulated genes are hypo-acetylated in Huntington's disease models.

Sadri-Vakili G, Bouzou B, Benn CL, Kim MO, Chawla P, Overland RP, Glajch KE, Xia E, Qiu Z, Hersch SM, Clark TW, Yohrling GJ, Cha JH.

Hum Mol Genet. 2007 Jun 1;16(11):1293-306. Epub 2007 Apr 4.

12.

Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease.

Gardian G, Browne SE, Choi DK, Klivenyi P, Gregorio J, Kubilus JK, Ryu H, Langley B, Ratan RR, Ferrante RJ, Beal MF.

J Biol Chem. 2005 Jan 7;280(1):556-63. Epub 2004 Oct 19.

13.

SAHA decreases HDAC 2 and 4 levels in vivo and improves molecular phenotypes in the R6/2 mouse model of Huntington's disease.

Mielcarek M, Benn CL, Franklin SA, Smith DL, Woodman B, Marks PA, Bates GP.

PLoS One. 2011;6(11):e27746. doi: 10.1371/journal.pone.0027746. Epub 2011 Nov 28.

14.

Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease.

Hockly E, Richon VM, Woodman B, Smith DL, Zhou X, Rosa E, Sathasivam K, Ghazi-Noori S, Mahal A, Lowden PA, Steffan JS, Marsh JL, Thompson LM, Lewis CM, Marks PA, Bates GP.

Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):2041-6. Epub 2003 Feb 7.

15.

Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice.

Ferrante RJ, Kubilus JK, Lee J, Ryu H, Beesen A, Zucker B, Smith K, Kowall NW, Ratan RR, Luthi-Carter R, Hersch SM.

J Neurosci. 2003 Oct 15;23(28):9418-27.

16.

Modulation of nucleosome dynamics in Huntington's disease.

Stack EC, Del Signore SJ, Luthi-Carter R, Soh BY, Goldstein DR, Matson S, Goodrich S, Markey AL, Cormier K, Hagerty SW, Smith K, Ryu H, Ferrante RJ.

Hum Mol Genet. 2007 May 15;16(10):1164-75. Epub 2007 Apr 2.

17.

Genome-wide histone acetylation is altered in a transgenic mouse model of Huntington's disease.

McFarland KN, Das S, Sun TT, Leyfer D, Xia E, Sangrey GR, Kuhn A, Luthi-Carter R, Clark TW, Sadri-Vakili G, Cha JH.

PLoS One. 2012;7(7):e41423. doi: 10.1371/journal.pone.0041423. Epub 2012 Jul 27.

18.

Hdac6 knock-out increases tubulin acetylation but does not modify disease progression in the R6/2 mouse model of Huntington's disease.

Bobrowska A, Paganetti P, Matthias P, Bates GP.

PLoS One. 2011;6(6):e20696. doi: 10.1371/journal.pone.0020696. Epub 2011 Jun 3.

19.

HDAC inhibitor sodium butyrate reverses transcriptional downregulation and ameliorates ataxic symptoms in a transgenic mouse model of SCA3.

Chou AH, Chen SY, Yeh TH, Weng YH, Wang HL.

Neurobiol Dis. 2011 Feb;41(2):481-8. doi: 10.1016/j.nbd.2010.10.019. Epub 2010 Nov 1.

PMID:
21047555
20.

Neuroprotective effects of PPAR-γ agonist rosiglitazone in N171-82Q mouse model of Huntington's disease.

Jin J, Albertz J, Guo Z, Peng Q, Rudow G, Troncoso JC, Ross CA, Duan W.

J Neurochem. 2013 May;125(3):410-9. doi: 10.1111/jnc.12190. Epub 2013 Mar 5.

Items per page

Supplemental Content

Write to the Help Desk